Skip to main content

Table 1 Comparison of baseline characteristics across patients with low (< 20 mg/L) vs. high (≥ 20 mg/L) CZP serum level

From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Axial spondyloarthritis

All

CZP low (< 20 mg/L)

CZP high (≥ 20 mg/L)

P value

(n = 116)

(n = 26)

(n = 90)

 Age, years, mean (SD)

42 (12)

43 (11)

41 (12)

0.61

 Female, n (%)

54 (47)

14 (54)

40 (44)

0.40

 Disease duration, years, median (IQR)*

2.6 (0.6–14.1)

3.6 (1.7–11.7)

2.3 (0.3–14.8)

0.39

 ASDAS-CRP, mean (SD)

2.6 (1.0)

2.4 (0.9)

2.7 (1.0)

0.28

 HLA-B27 positive, n (%)

87 (75)

17 (65)

70 (81)

0.09

 Prior use of biologic DMARD, n (%)

39 (34)

10 (40)

29 (33)

0.54

 Concomitant conventional synthetic DMARD, n (%)

22 (19)

2 (8)

20 (22)

0.10

Rheumatoid arthritis

All

CZP low (< 20 mg/L)

CZP high (≥ 20 mg/L)

P value

(n = 91)

(n = 23)

(n = 68)

 Age, years, mean (SD)

54 (14)

54 (16)

54 (14)

0.90

 Female, n (%)

72 (79)

13 (57)

59 (87)

< 0.05

 Disease duration, years, median (IQR)**

10.1 (2.1–18.9)

17.4 (6.8–23.5)

7.4 (2.0–14.9)

0.10

 DAS28, mean (SD)

4.0 (1.4)

3.5 (1.1)

4.2 (1.5)

0.08

 RF-positive, n (%)

55 (61)

12 (52)

43 (66)

0.23

 Anti-CCP positive, n (%)

59 (66)

13 (57)

46 (71)

0.21

 Prior use of biologic DMARD, n (%)

44 (48)

14 (64)

30 (45)

0.13

 Concomitant conventional synthetic DMARD, n (%)

67 (74)

16 (70)

51 (75)

0.53

Psoriatic arthritis

All

CZP low (< 20 mg/L)

CZP high (≥ 20 mg/L)

P value

(n = 61)

(n = 17)

(n = 44)

 Age, years, mean (SD)

50 (11)

48 (12)

51 (11)

0.45

 Female, n (%)

40 (66)

12 (71)

28 (64)

0.61

 Disease duration, years, median (IQR)***

6.6 (1.5–13.2)

5.4 (1.3–13.5)

6.9 (1.6–13.2)

0.76

 DAS28, mean (SD)

3.9 (1.3)

3.9 (1.8)

3.9 (1.2)

0.99

 Prior use of biologic DMARD, n (%)

30 (49)

10 (59)

20 (47)

0.39

 Concomitant conventional synthetic DMARD, n (%)

38 (67)

8 (53)

30 (71)

0.20

  1. Data available in n = *68, **68, ***40 patients
  2. CZP certolizumab pegol, ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C-reactive protein, DAS28 28-joint Disease Activity Score, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptides, DMARD disease-modifying antirheumatic drug, SD standard deviation, IQR interquartile range